Gilead’s Experimental Hepatitis C Drug Cured 88% Post-Therapy
This article is for subscribers only.
Gilead Sciences Inc.’s experimental hepatitis C drug cleared the virus in 88 percent of patients four weeks after treatment ended in a study, the company said today.
A combination of Gilead’s 7977 drug and the antiviral ribavirin cleared 22 out of 25 patients who hadn’t tried other medications after 12 weeks on the therapy, the Foster City, California-based company said at the European Association for the Study of Liver meeting in Barcelona.